The E-cadherin-GFP mouse allows in situ quantification of E-cadherin mobility
We monitored E-cadherin mobility during tissue homeostasis and disease development
Invasive pancreatic cancer driven by mutant Kras/p53 increases E-cadherin mobility
Dasatinib treatment reverts E-cadherin mobility and reinforces tumor cell junctions